Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

30. März 2020 07:30 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use

Expects to treat more patients in Israel in the coming daysCompany is in discussions with regulators in the U.S. and Europe to define its clinical strategy for COVID-19 HAIFA, Israel, March 30, 2020...
26. März 2020 08:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Provides Update on COVID-19: Preparedness, Current Phase III Clinical Trials Status and Treatment Development Activity

HAIFA, Israel, March 26, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
17. März 2020 08:30 ET | Quelle: Pluristem Therapeutics, Inc.

Israeli Ministry of Health Clears a Path to Allow Per Patient Compassionate Use Treatment of Covid-19 Patients with Pluristem’s PLX Cells

HAIFA, Israel, March 17, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
12. März 2020 09:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19

HAIFA, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- HAIFA, Israel, March 12, 2020 - Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform...
03. März 2020 07:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Receives Response from U.S. BARDA for Acute Radiation Syndrome Research Proposal

HAIFA, Israel, March 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
10. Februar 2020 07:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Therapeutics CEO Issues Shareholder Update

HAIFA, Israel, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel cell therapy products,...
03. Februar 2020 07:00 ET | Quelle: Pluristem Therapeutics, Inc.

In Its Path Towards Marketing, Pluristem Provides Highly Favorable Market Access Data Regarding the Critical Limb Ischemia Market in U.S.

HAIFA, Israel, Feb. 03, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products,...
17. Dezember 2019 07:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study

HAIFA, Israel, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
03. Dezember 2019 07:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment

HAIFA, Israel, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...
12. November 2019 07:00 ET | Quelle: Pluristem Therapeutics, Inc.

Pluristem Therapeutics CEO Issues Shareholder Update

HAIFA, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products,...

Vorherige Seite

Nächste Seite